A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

The objective of this study was to determine the objective response rate in patients with platinum-sensitive and platinum-resistant recurrent ovarian cancer to treatment with trabectedin (Yondelis®) administered as a 3-h infusion weekly for 3 weeks of a 4-week cycle. We carried out a multicentre Pha...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Krasner, C N, McMeekin, D S, Chan, S, Braly, P S, Renshaw, F G, Kaye, S, Provencher, D M, Campos, S, Gore, M E
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2007
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360276/
https://ncbi.nlm.nih.gov/pubmed/18000504
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604088
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi